secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0000950170-24-048364
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma Q1 net loss $2.0M, cash $35.9M; Oruka merger and CEO change detailed
--------------------------------------------------------------------------------

- Net loss for Q1 2024 was $2.0M ($0.14 per share) vs $1.3M ($0.09) in Q1 2023.
- Cash and equivalents $35.9M at March 31, 2024, down from $37.4M at Dec. 31, 2023; funds operations through mid-2025.
- G&A expenses rose to $2.3M from $1.4M due to $1.1M in professional fees related to the Oruka merger.
- CEO Michael Bristow separated effective April 3, 2024; Thomas Keuer appointed President and principal executive officer.
- Merger with Oruka Therapeutics is subject to conditions; failure could lead to dissolution or alternative strategic transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/0000950170-24-048364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/abio-20240425.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-048364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer